Results 11 to 20 of about 510,697 (405)

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Arthritis & Rheumatology, 2023
Brepocitinib is a TYK2/JAK1 inhibitor in development for the treatment of several immunologic diseases. The efficacy and safety of oral brepocitinib were assessed in participants with moderately‐to‐severely active psoriatic arthritis (PsA) for up to 52 ...
P. Mease, P. Helliwell, Paula Silwinska-Stanczyk, M. Miakisz, A. Ostor, E. Peeva, M. Vincent, Qiankun Sun, V. Sikirica, R. Winnette, R. Qiu, Gang Li, G. Feng, J. Beebe, D. Martin   +14 more
semanticscholar   +1 more source

Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study [PDF]

Терапевтический архив, 2018
Objectives: to study efficacy of treat-to-target (T2T) strategy in early peripheral psoriatic arthritis (EPsA) after one year of treatment. Methods: 44 (M/F - 18/26) DMARD-naїve patients (pts) with active EPsA, according to the CASPAR criteria, mean age ...
T V Korotaeva, E Yu Loginova, T S Getiya, E L Nasonov   +3 more
doaj   +1 more source

Search for predictors of psoriatic arthritis in patients with psoriasis [PDF]

Vestnik Dermatologii i Venerologii, 2023
Background. Psoriatic arthritis is a chronic inflammatory disease of the joints, spine and entheses that can occur in patients with psoriasis. The prevalence of psoriatic arthritis is 19.7%.
Olga G. Artamonova, Arfenya E. Karamova, Alexey A. Kubanov, Dmitry A. Verbenko, Irina V. Kozlova   +4 more
doaj   +1 more source

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.

New England Journal of Medicine, 2021
BACKGROUND The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor α inhibitor, in patients who have an inadequate response to ...
I. McInnes, Jaclyn K Anderson, M. Magrey, J. Merola, Yi Liu, M. Kishimoto, S. Jeka, C. Pacheco-Tena, Xin Wang, Liang Chen, P. Zueger, John Liu, A. Pangan, F. Behrens   +13 more
semanticscholar   +1 more source

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Acta Dermato-Venereologica, 2022
Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.
A. Gottlieb, A. Deodhar, I. McInnes, X. Baraliakos, K. Reich, S. Schreiber, W. Bao, K. Marfo, H. Richards, L. Pricop, A. Shete, V. Trivedi, Deborah Keefe, C. Papavassilis, P. Jagiello, P. Papanastasiou, P. Mease, M. Lebwohl   +17 more
semanticscholar   +1 more source

Psoriatic Arthritis.

New England Journal of Medicine, 2017
C. Ritchlin, R. Colbert, D. Gladman
semanticscholar   +8 more sources

Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis: A Bidirectional 2-Sample Mendelian Randomization Study.

JAMA dermatology, 2022
Importance Psoriasis, psoriatic arthritis, and inflammatory bowel disease, ie, Crohn disease and ulcerative colitis, are chronic systemic immune-mediated disorders affecting an increasing proportion of adults and children worldwide. Observational studies
D. Freuer, J. Linseisen, C. Meisinger
semanticscholar   +1 more source

Comorbidities in psoriatic arthritis: a systematic review and meta-analysis

Rheumatology International, 2021
The aims of this systematic review and meta-analysis were to: (1) describe the prevalence of commonly reported comorbidities in psoriatic arthritis (PsA), (2) compare the incidence and/or prevalence of comorbidities between PsA and control populations ...
Sonal Gupta, Zoe J Syrimi, D. Hughes, S. Zhao   +3 more
semanticscholar   +1 more source

Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: A Prospective Observational Cohort

Acta Dermato-Venereologica, 2022
Patients with psoriasis are at risk of developing psoriatic arthritis, which can lead to irreversible joint damage. However, a proportion of patients with psoriasis and concomitant psoriatic arthritis remain undiscovered in practice.
Tamara W. van Hal, Michelle L.M. Mulder, Mark H. Wenink, Marcel C. Pasch, Frank H.J. van den Hoogen, Juul M.P.A. van den Reek, Elke M.G.J. de Jong   +6 more
doaj   +1 more source

The Association of Psoriatic Arthritis with Carotid Intima-Media Thickness [PDF]

Journal of Kerman University of Medical Sciences, 2021
Background: Previous studies have showed that psoriatic arthritis increases the risk of cardiovascular disease and atherosclerosis. On the other hand, an increased carotid intima-media thickness can be associated with atherosclerosis.
Hamidreza Talari, Mojtaba Sehat, Mohammad Shayestehpour, Khatereh Minaee, Batool Zamani   +4 more
doaj   +1 more source